Cape Cod Healthcare advancing lung cancer detection with state-of-the-art biopsy technology

(Hyannis, MA, January 13, 2025) – As a complement to an established Lung Nodule Program focused on regular low-dose CT scan (LDCT) screening for at-risk patients, Cape Cod Healthcare now offers the Ion Robotic-Assisted Bronchoscopy platform as an optimal option for qualifying patients needing lung biopsy procedures. This initiative is championed by thoracic surgeon Dr. Jeff Spillane and interventional pulmonologist Dr. Michael Ayers, both of whom are extensively trained in robotic bronchoscopy.

Lung cancer remains the leading cause of cancer death worldwide, and earlier detection can make a critical difference in patient outcomes for a disease that takes an estimated 1.8 million lives a year. With 44% of lung cancer cases diagnosed at a late stage - when survival rates fall to just 7%, - early detection and treatment is crucial.

Developed by Intuitive, a leader in robotic-assisted technology, Ion’s minimally invasive biopsy technology helps detect lung cancer earlier and ultimately improves patient outcomes, with more stability and more precision as compared to manual biopsy techniques and without the need for invasive surgery or needle biopsies that puncture the skin.

Ion features a thin and maneuverable catheter allowing deeper airway navigation and enabling physicians to obtain tissue samples from deep within the lung – a traditionally challenging aspect of lung biopsy.

“This expansion of our minimally invasive robotic technology further strengthens our commitment to delivering quality and safe care to our community,” says Michael Lauf, President and CEO of Cape Cod Healthcare. “Continuous improvement in lung cancer detection plays a key role in ensuring our patients on Cape Cod experience longer, healthier lives.”